Skip to content

Search

T-cell activation genes differentially expressed at birth in CD4+ T-cells from children who develop IgE food allergy

To show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.

A genomics-based approach to assessment of vaccine safety and immunogenicity in children

This methodology has significant potential to identify covert interactions between inflammatory pathways triggered by vaccination, and as such may be a...

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort study

Atopy and asthma are commonly initiated during early life, and there is increasing interest in the development of preventive treatments for at-risk children.

Michael Serralha

Michael Serralha is a Research Assistant in the Chronobiology and ORIGINS teams at The Kids Research Institute Australia.

Searching for a technology-driven acute rheumatic fever test: the START study protocol

The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus.

Breastfeeding and Neonatal Age Influence Neutrophil-Driven Ontogeny of Blood Cell Populations in the First Week of Human Life

The first few days of life are characterized by rapid external and internal changes that require substantial immune system adaptations. Despite growing evidence of the impact of this period on lifelong immune health, this period remains largely uncharted. 

Understanding how viral infection in early life impacts on lung function in adulthood

Alexander David Deborah Larcombe Martino Strickland BScEnv (Hons) PhD BSc PhD PhD Honorary Research Fellow Head, Chronic Diseases Research Head,

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.